Indeed, perhaps non-immune causes of neuronal destruction are sufficient to release immunogenic Kv1 antigens and provoke autoantibody production.16, 22, 26 Interestingly, the immunotherapy response observed in 27% of patients is very similar to the placebo response rates observed in several other neurological diseases,37 and much lower than those reported in LGI1 or CASPR2 antibody-associated syndromes.7–9, 11, 15, 29, 35 However, conclusions regarding treatment outcomes are only definitive after blinded interventional studies. This evidence concerns the gene CNTNAP2 and nervous system disorder.